Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization

Tuesday, 29th of December 2015

Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization

Meyer SA¹, Kambou JL², Cohn A³, Goodson JL⁴, Flannery B⁵, Medah I⁶, Messonnier N⁷, Novak R⁸, Diomande F⁹, Djingarey MH¹⁰, Clark TA¹¹, Yameogo I¹², Fall A¹³, Wannemuehler K¹⁴.

Author information

¹Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS E92, Atlanta, GA 30333, United States. Electronic address: smeyer@cdc.gov.
²Direction de la Prévention par les Vaccinations, Burkina Faso Ministry of Health, 03 BP 7009 Ouagadougou, Burkina Faso. Electronic address: kambouludo@hotmail.com.
³Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: anc0@cdc.gov.
⁴Global Immunizations Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A04, Atlanta, GA 30333, United States. Electronic address: fez9@cdc.gov.
⁵Global Immunizations Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A04, Atlanta, GA 30333, United States. Electronic address: bif4@cdc.gov.
⁶Direction de la Lutte contre la Maladie, Burkina Faso Ministry of Health, 03 BP 7009 Ouagadougou, Burkina Faso. Electronic address: isaiemedah@yahoo.fr.
⁷Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: nar5@cdc.gov.
⁸Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: bnk4@cdc.gov.
⁹Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: fed2@cdc.gov.
¹⁰World Health Organization Intercountry Support Team for West Africa, 158 Avenue de lIndépendance, 03 BP 7019 Ouagadougou, Burkina Faso. Electronic address: djingareyh@who.int.
¹¹Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: tnc4@cdc.gov.
¹²Direction de la Lutte contre la Maladie, Burkina Faso Ministry of Health, 03 BP 7009 Ouagadougou, Burkina Faso. Electronic address: yameogoissaka@yahoo.fr.
¹³World Health Organization Intercountry Support Team for West Africa, 158 Avenue de lIndépendance, 03 BP 7019 Ouagadougou, Burkina Faso. Electronic address: falla@who.int.
¹⁴Global Immunizations Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A04, Atlanta, GA 30333, United States. Electronic address: kpw9@cdc.gov.

Vaccine. 2015 Mar 17;33(12):1492-8. doi: 10.1016/j.vaccine.2015.01.043. Epub 2015 Jan 28.

Abstract below ; full text is at http://www.sciencedirect.com/science/article/pii/S0264410X15000870

BACKGROUND:

A new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) has been developed to combat devastating serogroup A Neisseria meningitis (MenA) epidemics in Africa. A mass immunization campaign targeting 1-29 year olds was conducted in Burkina Faso in December 2010. Protection of subsequent infant cohorts will be necessary through either introduction of PsA-TT into the routine Expanded Programme on Immunization (EPI) or periodic repeat mass vaccination campaigns.

OBJECTIVES:

To inform future immunization policy for PsA-TT vaccination of infants through a comparison of PsA-TT campaign vaccination coverage and routine measles-containing vaccine (MCV) coverage in Burkina Faso.

METHODS:

A national survey was conducted in Burkina Faso during December 17-27, 2011 using stratified cluster sampling to assess PsA-TT vaccine coverage achieved by the 2010 nationwide immunization campaign among 2-30 year olds and routine MCV coverage among 12-23 month olds. Coverage estimates and 95% Confidence Intervals (CI) were calculated, reasons for non-vaccination and methods of campaign communication were described, and a multivariable analysis for factors associated with vaccination was conducted.

RESULTS:

National overall PsA-TT campaign coverage was 95.9% (95% CI: 95.0-96.7) with coverage greater than 90% all 13 regions of Burkina Faso. National overall routine MCV coverage was 92.5% (95% CI: 90.5-94.1), but ranged from 75.3% to 95.3% by region. The primary predictor for PsA-TT vaccination among all age groups was a head of household informed of the campaign. PsA-TT vaccination was more likely in residents of rural settings, whereas MCV vaccination was more likely in residents of urban settings.

CONCLUSION:

Overall national vaccination rates in Burkina Faso were similar for PsA-TT and MCV vaccine. The regions with MCV coverage below targets may be at risk for sub-optimal vaccination coverage if PsA-TT is introduced in EPI. These results highlight the need for assessments of routine vaccination coverage to guide PsA-TT immunization policy in meningitis belt countries.

Published by Elsevier Ltd.

Similar articles